GTBP: Phase I TriKE trials show early promise, with key data expected soon and broad expansion potential

The TriKE platform is advancing in phase I trials for both blood cancers and solid tumors, showing early signs of safety and efficacy, with flexible application potential across oncology and autoimmune diseases. Key data readouts are expected by year-end, and the platform's cost-effectiveness and o…